Purification of Activated Bovine Hageman Factor

Summary

Activated Hageman Factor has been purified 3000 to 5000 fold from citrated bovine plasma as measured in a thoroughly devised assay procedure. The steps of purification include adsorption on aluminium hydroxide gel, glass, diethyl- aminoethyl cellulose and Sephadex G-200. A fractionation according to Cohn between step 2 and 3 renders the factor more stable for further purification. The purified preparations corrected the clotting defect in human plasma with Hageman trait. The most purified fractions were devoid of plasma thromboplastin antecedent (PTA), other clotting factors.

^* This study was supported in part by the Organisation for Health Research, T N O, the Netherlands.

• References

• 1 Ratnoff O. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass: evidence that glass frees Hageman factor from inhibition. Amer. J. Med. 25: 160 1958;
• 2 Vroman L. Surface contact and thromboplastin formation. Thesis: University of Utrecht; 1958
• 3 Johnston C. L, Ferguson J. H, O’Hanlon F. A. Surface activation of plasma clotting: a function of Hageman factor. Proc. Soc. exp. Biol. (N. Y) 99: 197 1958;
• 4 Soulier J. P, Wartelle O, Ménaché D. Hageman trait and PTA deficiency: the role of contact of blood with glass. Brit. J. Haemat. 05: 121 1959;
• 5 Waaler B. A. Contact activation in the intrinsic blood clotting system. Studies on a plasma product formed on contact with glass and similar surfaces. Scand. J. clin. Lab. Invest 11 Suppl. 37 1959;
• 6 Margolis J. Activation of plasma by contact with glass: evidence for a common reaction which releases plasma kinin and initiates coagulation. J. Physiol., Lond 144: 1 1958;
• 7 Hardisty R. M, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit. J. Haemat. 05: 203 1959;
• 8 Ratnoff O. D, Davie E. W, Mallett D. L. Studies on the action of Hageman factor: Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J. clin. Invest 40: 813 1961;
• 9 Schiffman S, Rapaport S. I, Ware A. G, Mehl J. W. Separation of PTA and HF from human plasma. Proc. Soc. exp. Biol. (N. Y) 105: 453 1960;
• 10 Haanen C, Hommes F, Benraad H, Morselt G. A Case of Hageman- Factor Deficiency and a Method to Purify the Factor. Thrombos. Diathes. haemorrh. (Stuttg) 05: 201 1961;
• 11 Didisheim P. Purification of Hageman factor. Fed. Proc. 20. March 1961
• 12 Ratnoff O. D, Davie E. W. The Purification of Activated Hageman Factor (Activated Factor XII. Biochemistry. 01: 967 1962;
• 13 Rapaport S. I, Schiffman S, Patch M. J, Ware A. G. A simple, specific one-stage assay for Plasma Thromboplastin Antecedent activity. J. Lab. clin. Med. 57: 771 1961;
• 14 Alkjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest 38: 1086 1959;
• 15 Astrup T, Miillertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem. 40: 346 1952;
• 16 von Kaulla K. N, Schultz R. L. Methods for the evaluation of human fibrinolysis. Amer. J. clin. Path. 29: 104 1958;
• 17 Iatridis S. G, Ferguson J. H. Effect of Surface and Hageman Factor on the Endogenous or Spontaneous Activation of the Fibrinolytic System. Thrombos. Diathes. haemorrh. (Stuttg) 06: 411 1961;
• 18 Christensen L. R. Methods for measuring activity of components of streptococcal fibrinolytic system and streptococcal desoxyribonuclease. J. clin. Invest 28: 163 1949;
• 19 Lowry O. H, Rosebrough N. J, Farr A. L, Randall R. J. Protein measurement with the Folin Phenol reagent. J. biol. Chem. 193: 265 1951;
• 20 Iatridis S. G, Ferguson J. H. Active Hageman Factor: J. clin. Invest 41: 1277 1962;
• 21 Cohn E. J, Strong L. T, Hughes W. L, Mulford D. J, Ashworth J. N, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Amer. chem. Soc. 68: 459 1946;
• 22 Smithies O. An Improved Procedure for Starch-gel Electrophoresis: Further Variations in the Serum Proteins of Normal Individuals. Biochem. J. 71: 585 1959;
• 23 Davis B. J, Ornstein L. Disc. Electrophoresis. Preprinted by Destillation Products Industries. Rochester, USA.:
• 24 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII. Act. haemat. (Basel) 06: 1 1951;
• 25 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 03: 201 1951;
• 26 Niewiarowski S, Prou-Wartèlle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg) 03: 593 1959;
• 27 Gelotte B, Flodin P, Killander J. Fractionation of Human Plasma by Gel Filtration and Zone Electrophoresis or Ion-Exchange Chromatography. Arch. Biochem. Suppl. 01: 319 1962;